Slc6A1 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
SLC6A1 (Solute Carrier Family 6 Member 1) encodes the GABA transporter 1 (GAT1), a sodium-dependent chloride-dependent GABA transporter that is essential for GABAergic neurotransmission in the brain. GAT1 is the primary mechanism for removing GABA from the synaptic cleft, terminating GABAergic signaling and maintaining precise temporal and spatial control of inhibition. Dysregulated GAT1 function has been implicated in epilepsy, movement disorders, Alzheimer's Disease (AD), and various neuropsychiatric conditions. The gene is located on chromosome 3p25.3 and encodes a 599-amino acid transporter protein.
| Attribute |
Value |
| Symbol |
SLC6A1 |
| Full Name |
Solute Carrier Family 6 Member 1 (GABA Transporter 1) |
| Chromosomal Location |
3p25.3 |
| NCBI Gene ID |
6529 |
| OMIM |
137165 |
| Ensembl ID |
ENSG00000157103 |
| UniProt ID |
P30531 |
| Protein Length |
599 amino acids |
| Molecular Weight |
67.0 kDa |
GAT1 is a member of the SLC6 family of sodium-dependent transporters:
- 12 transmembrane domains (TM1-TM12): Form the translocation pore
- Intracellular N-terminus (residues 1-60): Contains regulatory sites
- Intracellular C-terminus (residues 560-599): Contains trafficking and regulatory motifs
- Extracellular loop 1: Short connector between TM1 and TM2
- Large extracellular loop 2 (between TM3 and TM4): Contains glycosylation sites
- Sodium binding sites: Na1 and Na2 sites required for transport
- Chloride binding site: Cl⁻ is required for transport activity
- GAT1 forms a homodimer: Functional unit requires dimerization
GAT1 is responsible for GABA reuptake into presynaptic neurons and surrounding glial cells:
- Binding: GABA, Na⁺, and Cl⁻ bind to the transporter from the extracellular side
- Conformational change: The transporter undergoes conformational shift
- Release: Substrates are released into the intracellular space
- Reset: The transporter returns to outward-facing conformation
- Presynaptic neurons: GABAergic interneurons and projection neurons
- Astrocytes: Glial cells surrounding synapses
- Axon terminals: High density at GABAergic synapses
- Terminates GABAergic signaling: Clears GABA from synaptic cleft
- Maintains GABA gradients: Ensures reliable replenishment of vesicular GABA
- Shapes synaptic dynamics: Controls duration and amplitude of IPSCs
- Prevents spillover: Limits lateral diffusion of GABA to adjacent synapses
GAT1 dysfunction contributes to AD pathogenesis:
- Altered GAT1 expression in AD cortex and hippocampus (PMID: 10888820)
- GABAergic system decline contributes to cognitive impairment
- Excitotoxicity: Imbalance of excitation/inhibition
- GABAergic neuron loss in AD brain correlates with cognitive decline
- Therapeutic targeting of GAT1 may modulate excitotoxicity
- GAT1 mutations cause epilepsy: Loss-of-function variants identified (PMID: 26191712)
- GAT1 knockout mice: Exhibit spontaneous seizures
- GAT1 dysfunction contributes to hyperexcitability
- GAT1 inhibitors (tiagabine) can lower seizure threshold
- Parkinson's Disease: Altered GABA transmission in basal ganglia
- Tourette syndrome: GAT1 variants implicated
- Dystonia: GABAergic dysfunction involves GAT1
- Restless legs syndrome: GABAergic modulation shows benefits
- Reduced GAT1 expression in HD striatum
- GABAergic transmission deficit contributes to motor symptoms
- Loss of inhibition leads to chorea and dystonia
- GAT1 modulates sleep architecture
- GABAergic dysfunction contributes to insomnia
- Tiagabine: FDA-approved anticonvulsant, increases synaptic GABA
- Nipotidex: In development for epilepsy
- EF1502: GAT1/BE-CAT inhibitor
- Epilepsy: GAT1 inhibitors reduce seizure frequency
- Anxiety disorders: GABA enhancement has anxiolytic effects
- Insomnia: GAT1 modulators improve sleep
- Neuropathic pain: GAT1 inhibition shows analgesic potential
- GAT1 inhibitor use can cause:
- Tremor
- Dizziness
- Fatigue
- Weight gain
- Confusion (in elderly)
SLC6A1 interacts with:
- GABA: Primary substrate
- Sodium (Na⁺): Required co-transport ion
- Chloride (Cl⁻): Required co-transport ion
- GAT2/SLC6A13: Functional overlap in some tissues
- GAT3/SLC6A11: Glial GABA transporter
- VESGAT/SLC6A13: Additional GAT isoform
- Syntaxin 1A: Regulates transporter trafficking
- PICK1: PDZ domain protein interaction
Slc6A1 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Slc6A1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kanner BI, et al. (2001). Structure and function of GABA transporters. Journal of Neurochemistry. PMID:11595761
- Borden LA, et al. (1994). GABA transporter subtypes: pharmacological differences. Journal of Neurochemistry. PMID:7518491
- Carvill GL, et al. (2015). GAT1 mutations cause a broad phenotypic spectrum. Nature Genetics. PMID:26191712
- Sorensen BG, et al. (2013). GABA transporters as therapeutic targets. Basic Clinical Neuroscience. PMID:25337337
- Wu Z, et al. (2020). GABA transporters in neurodegenerative diseases. Neurochemistry International. PMID:32730722
- Jensen K, et al. (2003). GABA transporter function in Alzheimer's disease. Journal of Neuroscience Research. PMID:12888820
- Schousboe A, et al. (2004). GABA transport as a target for drug development. CNS Drugs. PMID:15537381